BR9813254A - Antìgeno enterococcus e vacinas - Google Patents

Antìgeno enterococcus e vacinas

Info

Publication number
BR9813254A
BR9813254A BR9813254-7A BR9813254A BR9813254A BR 9813254 A BR9813254 A BR 9813254A BR 9813254 A BR9813254 A BR 9813254A BR 9813254 A BR9813254 A BR 9813254A
Authority
BR
Brazil
Prior art keywords
antigen
carrier
vaccines
galactose
enterococcus antigen
Prior art date
Application number
BR9813254-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Ali Ibrahim Fattom
Ramesh K Sood
Sara E Shepherd
Original Assignee
Nabi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi filed Critical Nabi
Publication of BR9813254A publication Critical patent/BR9813254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR9813254-7A 1997-10-14 1998-10-14 Antìgeno enterococcus e vacinas BR9813254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/949,757 US6756361B1 (en) 1997-10-14 1997-10-14 Enterococcus antigens and vaccines
PCT/US1998/021561 WO1999018996A1 (en) 1997-10-14 1998-10-14 Enterococcus antigens and vaccines

Publications (1)

Publication Number Publication Date
BR9813254A true BR9813254A (pt) 2001-11-20

Family

ID=25489514

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813254-7A BR9813254A (pt) 1997-10-14 1998-10-14 Antìgeno enterococcus e vacinas

Country Status (14)

Country Link
US (2) US6756361B1 (OSRAM)
EP (3) EP1028749B1 (OSRAM)
JP (2) JP2001519402A (OSRAM)
AT (1) ATE397456T1 (OSRAM)
AU (1) AU754890B2 (OSRAM)
BR (1) BR9813254A (OSRAM)
CA (1) CA2306476A1 (OSRAM)
CY (1) CY1108307T1 (OSRAM)
DE (1) DE69839587D1 (OSRAM)
DK (1) DK1028749T3 (OSRAM)
ES (1) ES2308818T3 (OSRAM)
NZ (1) NZ504501A (OSRAM)
PT (1) PT1028749E (OSRAM)
WO (1) WO1999018996A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905670B2 (en) 1995-03-28 2005-06-14 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7078584B2 (en) 2000-03-17 2006-07-18 The General Hospital Corporation Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection
US7112716B2 (en) 2000-04-06 2006-09-26 The General Hospital Corporation Methods for screening and identifying host pathogen defense genes
US6710403B2 (en) 2002-07-30 2004-03-23 Fairchild Semiconductor Corporation Dual trench power MOSFET
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP1998800A2 (en) 2006-01-18 2008-12-10 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
EP3281947B1 (en) 2009-04-03 2020-02-12 The University of Chicago Compositions and methods related to protein a (spa) variants
EP2443250B8 (en) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
US9125846B2 (en) 2010-10-15 2015-09-08 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011088843A1 (en) * 2010-01-19 2011-07-28 Universitätsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2526951B1 (en) * 2011-05-27 2015-09-30 Universitätsklinikum Freiburg Rhamno-polysaccharide from Enterococcus faecium clonal complex 17 and uses thereof
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
EP2915543B1 (en) * 2014-03-04 2018-05-09 Albert-Ludwigs-Universität Freiburg Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2466251B1 (fr) * 1979-10-03 1983-03-18 Agronomique Inst Nat Rech Vaccin animal anticolibacillaire, obtention et application
US4439422A (en) 1980-01-02 1984-03-27 Research Corporation Group B Streptococcus antigens and vaccines
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
JPS5927833A (ja) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
JPS6028401A (ja) 1983-07-27 1985-02-13 Advance Res & Dev Co Ltd トリグリセリド低下活性多糖類
US4626502A (en) * 1984-01-27 1986-12-02 Abbott Laboratories Method for exposing bacterial antigen in bacterial cells assay using same
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8414273D0 (en) * 1984-06-05 1984-07-11 Oxoid Ltd Identifying streptococcal grouping
JPS615022A (ja) * 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
GB8517895D0 (en) * 1985-07-16 1985-08-21 Technology Licence Co Ltd Monoclonal antibodies
US4695524A (en) * 1986-05-21 1987-09-22 Xerox Corporation Process for ultra high quality images with magnetic developer composition
US5143845A (en) * 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
WO1988002781A1 (en) * 1986-10-08 1988-04-21 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
US5032505A (en) 1988-11-21 1991-07-16 Chembiomed, Ltd. Inhibitors for glycosaminosyl transferase V
US5175279A (en) * 1989-01-19 1992-12-29 Hakuto Co., Ltd. Polysaccharide, and water absorbent, moisture absorbent or humectant and thickening agent chiefly made of the polysaccharide
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5858728A (en) * 1991-03-13 1999-01-12 Common Services Agency Monoclonal antibody against LPS core
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
US5205917A (en) * 1991-05-07 1993-04-27 Glyko, Inc. Fluorophore assisted carbohydrate electrophoresis diagnosis
AU666128B2 (en) * 1991-08-23 1996-02-01 Alberta Research Council Inc. Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
RU2101029C1 (ru) * 1992-11-26 1998-01-10 Товарищество с ограниченной ответственностью "ХИМЭК" Способ получения препарата для идентификации стрептококка группы д
GB9310468D0 (en) * 1993-05-20 1993-07-07 Oxford Glycosystems Ltd Sugar complexes
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
JPH0782158A (ja) * 1993-09-16 1995-03-28 Yakult Honsha Co Ltd 抗腫瘍剤
JP2717497B2 (ja) * 1993-12-28 1998-02-18 不二ラテックス株式会社 酸性多糖類被覆コンドーム
GB9401689D0 (en) * 1994-01-28 1994-03-23 Univ Manchester Diagnosis and treatment of endocarditis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5489302A (en) * 1994-05-24 1996-02-06 Skottun; Bernt C. Accommodating intraocular lens
JPH0827010A (ja) * 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5871751A (en) * 1994-10-12 1999-02-16 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Renibacterium salmoninarum vaccine and method for its preparation
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
WO1996039155A1 (en) * 1995-06-05 1996-12-12 Tayca Corporation Immunopotentiator
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US5989542A (en) * 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
US6722062B2 (en) * 1997-08-20 2004-04-20 The Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
DE69940371D1 (de) * 1998-09-14 2009-03-19 Nabi Biopharmaceuticals Rockvi Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
CA2364507A1 (en) * 1999-03-12 2000-09-14 University Of Massachusetts Lipoglycan compositions and methods of treating parasitic infections
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals

Also Published As

Publication number Publication date
US7291343B2 (en) 2007-11-06
US20050008658A1 (en) 2005-01-13
CY1108307T1 (el) 2014-02-12
WO1999018996A1 (en) 1999-04-22
EP1028749B1 (en) 2008-06-04
AU9694998A (en) 1999-05-03
EP1028749A4 (en) 2003-03-12
WO1999018996B1 (en) 1999-06-03
US6756361B1 (en) 2004-06-29
ATE397456T1 (de) 2008-06-15
JP2009227680A (ja) 2009-10-08
CA2306476A1 (en) 1999-04-22
EP1970073A1 (en) 2008-09-17
DE69839587D1 (de) 2008-07-17
PT1028749E (pt) 2008-09-04
NZ504501A (en) 2003-09-26
EP1028749A1 (en) 2000-08-23
DK1028749T3 (da) 2008-09-01
EP2269635A1 (en) 2011-01-05
AU754890B2 (en) 2002-11-28
ES2308818T3 (es) 2008-12-01
JP2001519402A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
DK1028749T3 (da) Enterococcus-antigener og -vacciner
WO1998058668A3 (en) Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
IL102687A (en) Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
IL154326A0 (en) Anti-dual integrin antibodies, compositions, methods and uses
PT835663E (pt) Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
EP0866133A3 (en) A group b streptococcus vaccine
FI903292A0 (fi) T-cellepitop som baerarmolekyler foer konjugerade vacciner.
ATE237687T1 (de) Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind
DE69925187D1 (de) Antigenkonjugate von konservierten Lipooligosacchariden aus gram-negativen Bakterien
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DK0473721T3 (da) Antiidiotypisk antistof, som fremkalder en immunreaktion med et glycosphingolipid, og anvendelse deraf
IL109445A0 (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
EP2057999A3 (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
ATE530572T1 (de) Antigen-cocktails, p35 und verwendungen dafür
EP0153871A3 (en) Antibody enhancement of immunogenicity of antigen
AU1423892A (en) Monoclonal antibodies directed towards mycobacterial antigens
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
ZA862620B (en) Histamine derivatives,immunogen conjugates and antibodies raised thereto
CA2333598A1 (en) Toxoplasma gondii antigens, p35, and uses thereof
EP0485476A4 (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ITRM910385A1 (it) Vaccini utilizzanti eritrociti come veicoli di antigeni
IL94304A0 (en) Novel tumor-associated antigen,antibodies,compositions and uses therefor
GB2267148B (en) Footrot antigens,vaccines and diagnostic assays
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: NABI BIOPHARMACEUTICALS (US)

Free format text: REFERENTE A RPI 1793 DE 17/05/2005, COD. DE DESPACHO 25.4, QUANTO AO NOME DO TITULAR.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS ANUIDADES EM DEBITO.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2316 DE 26-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.